Loading…
Loading…
Protocol
This page describes an oral-first research protocol built around the featured 1 mg enteric product. It is not a prescription or validated clinical regimen.
Featured product
Timeline
The featured oral form is 1 mg enteric capsules. The product page recommends morning use. Enteric coating aims to release the peptide in the small intestine, where PEPT1 transporters handle di- and tripeptides; luminal peptidase hydrolysis remains a real uncertainty.
Cycles in the Khavinson peptide literature commonly follow short-course on/off rhythms with multi-month pauses, often 4-6 months off. This is practice, not a validated Vilon RCT schedule.
Track sleep, recovery, infection frequency, and, if available, lymphocyte subsets and thymic output indicators. No human dose-response trial establishes the expected time course for Vilon specifically.
Peptide use should be paired with regular health monitoring. Stop and reassess if adverse symptoms appear. Formal human safety data are sparse in the retrieved corpus.
Compatible combinations
Common mistakes
Storage
Oral capsules
Store in a cool, dry place away from light and moisture. Do not expose enteric capsules to high heat or humidity.
Research vials
No Vilon-specific validated stability or reconstitution SOP was recovered. Follow the actual vial/COA protocol rather than importing generic timing. Reconstituted peptides are sensitive to temperature, light, and microbial contamination.
Foundation first
Sleep, exercise, nutrition, and stress management matter more than any peptide. No peptide should replace these basics.